Skip to main content

Table 1 Model parameters

From: The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients

Name

Description

Deterministic value

Probabilistic components

Source

   

Distribution

Range

 

Gamma

Alpha1

Alpha 2

 
    

Min

Max

    

cDR

Cost discount rate

0.035

Fixed

     

Pharmaco economic guidelines (NICE)

oDR

Outcome discount rate

0.035

Fixed

     

Pharmaco economic guidelines (NICE)

cArgus II

Costs of device + implantation

90800

BETA Pert

68100

113500

8

5

5

Second Sight

cRP

Annual health care costs incurred on RP patients

11789

BETA Pert

8841

14736

8

5

5

Frick et al. [14]

cVA+

Annual health care costs incurred on RP patients with VA+

9431

BETA Pert

7073

11789

8

5

5

Frick et al. [14] + assumption

cVA++

Annual health care costs incurred on RP patients with VA++

8252

BETA Pert

6189

10315

8

5

5

Frick et al. [14]+ assumption

cVA+++

Annual health care costs incurred on RP patients with VA+++

7073

BETA Pert

5305

8841

8

5

5

Frick et al. [14] + assumption

cSAE

Cost of management of Serious Adverse Event

1000

BETA Pert

750

1250

8

5

5

Expert opinion

cExplant

Cost of Explantation

2000

BETA Pert

1500

2500

8

5

5

Humayun et al. [9]/Second sight

cOthers

Annual other costs for Argus II patients (e.g. Upgrades etc.)

300

BETA Pert

225

375

8

5

5

Humayun et al. [9]/Second sight

pVA+

Argus II patient’s annual probability of getting VA+

0.74

BETA Pert

0.554

0.924

8

5

5

Humayun et al. [9]/Second Sight

pVA++

Argus II patient’s annual probability of getting VA++

0.21

BETA Pert

0.154

0.257

8

5

5

Humayun et al. [9]/Second sight

pVA+++

Argus II patient’s annual probability of getting VA++

0.04

BETA Pert

0.029

0.049

8

5

5

Humayun et al. [9]/Second sight

pSAE

Probability of Serious Adverse Event in Argus II patients in first year

0.3

BETA Pert

0.225

0.375

8

5

5

Humayun et al. [9]/Second Sight

pExplant

Argus II patient’s annual probability of device explantation

0.02

BETA Pert

0.013

0.021

8

5

5

Humayun et al. [9]/Second Sight

uRP

Utility value in RP patients

0.26

BETA Pert

0.195

0.325

8

5

5

Brown et al. [18]

uVA+

Utility value in RP patients with VA+

0.35

BETA Pert

0.263

0.438

8

5

5

Brown et al. [18]

uVA++

Utility value in RP patients with VA++

0.52

BETA Pert

0.39

0.65

8

5

5

Brown et al. [18]

uVA+++

Utility value in RP patients with VA+++

0.54

BETA Pert

0.405

0.675

8

5

5

Brown et al. [18]

uSAE

(dis) utility value in patients with Serious Adverse Events

0.16

BETA Pert

0.12

0.2

8

5

5

Schiffman et al. [19]

uExplant

Utility value in patients post Argus II explantation

0.26

BETA Pert

0.195

0.325

8

5

5

Assumption